Is Adherence to Imatinib Mesylate Treatment among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar?

Nader Al‐Dewik(St George's, University of London), Mohamed A. Yassin(Hamad Medical Corporation), Rola Ghasoub(National Center for Cancer Care and Research), Rana Al‐Jurf(Hamad Medical Corporation), Rani Khatib(University of Leeds), Tawfeg Ben‐Omran(Hamad General Hospital), Cinquea C. Gnanam(National Center for Cancer Care and Research), Ali A. Alsayab(Hamad Medical Corporation), Muthanna Samara(Kingston University), Mohammed Alsharshani(Hamad Medical Corporation), Abdulqadir J. Nashwan(Qatar Airways (Qatar)), Subi K. Bhaskaran(National Center for Cancer Care and Research), Mohamed A. Ismail(Hamad Medical Corporation), Hisham Morsi(St George's, University of London)
Clinical Medicine Insights Oncology
January 1, 2016
Cited by 39


Related Papers